ガレノキサシン
- ¥317900 - ¥746600
- 化学名: ガレノキサシン
- 英語名: Garenoxacin
- 別名:1-シクロプロピル-8-(ジフルオロメトキシ)-7-[(1R)-1-メチル-2,3-ジヒドロ-1H-イソインドール-5-イル]-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸;8-(ジフルオロメトキシ)-1,4-ジヒドロ-7-(2,3-ジヒドロ-1β-メチル-1H-イソインドール-5-イル)-1-シクロプロピル-4-オキソキノリン-3-カルボン酸;ガレノキサシン;1-シクロプロピル-8-(ジフルオロメトキシ)-7-(2,3-ジヒドロ-1β-メチル-1H-イソインドール-5-イル)-1,4-ジヒドロ-4-オキソキノリン-3-カルボン酸;1-シクロプロピル-8-(ジフルオロメトキシ)-7-[(1R)-1-メチルイソインドリン-5-イル]-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸;7-[(1R)-1β-メチルイソインドリン-5-イル]-1-シクロプロピル-8-(ジフルオロメトキシ)-4(1H)-オキソキノリン-3-カルボン酸
- CAS番号: 194804-75-6
- 分子式: C23H20F2N2O4
- 分子量: 426.41
- EINECS:
- MDL Number:MFCD08141853
2物価
選択条件:
ブランド
- 富士フイルム和光純薬株式会社(wako)
パッケージ
- 250mg
- 1g
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01MAS090188
- 製品説明
- 英語製品説明(R)-1-Cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- 包装単位250mg
- 価格¥317900
- 更新しました2024-03-01
- 購入
- 生産者富士フイルム和光純薬株式会社(wako)
- 製品番号W01MAS090188
- 製品説明
- 英語製品説明(R)-1-Cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- 包装単位1g
- 価格¥746600
- 更新しました2024-03-01
- 購入
生産者 | 製品番号 | 製品説明 | 包装単位 | 価格 | 更新時間 | 購入 |
---|---|---|---|---|---|---|
富士フイルム和光純薬株式会社(wako) | W01MAS090188 | (R)-1-Cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
250mg | ¥317900 | 2024-03-01 | 購入 |
富士フイルム和光純薬株式会社(wako) | W01MAS090188 | (R)-1-Cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
1g | ¥746600 | 2024-03-01 | 購入 |
プロパティ
融点 :226-227°; mp 234-235°
比旋光度 :D27 -9.0° (c = 0.10 in N,N-dimethylformamide)
沸点 :581.5±50.0 °C(Predicted)
比重(密度) :1.421±0.06 g/cm3(Predicted)
貯蔵温度 :Hygroscopic, -20°C Freezer, Under inert atmosphere
溶解性 :DMF (Slightly, Heated), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
外見 :Solid
酸解離定数(Pka) :6.44±0.50(Predicted)
色 :Off-White to Pale Yellow
安定性: :Hygroscopic
InChIKey :NJDRXTDGYFKORP-LLVKDONJSA-N
SMILES :N1(C2CC2)C2=C(C=CC(C3C=CC4=C(C=3)CN[C@@H]4C)=C2OC(F)F)C(=O)C(C(O)=O)=C1
比旋光度 :D27 -9.0° (c = 0.10 in N,N-dimethylformamide)
沸点 :581.5±50.0 °C(Predicted)
比重(密度) :1.421±0.06 g/cm3(Predicted)
貯蔵温度 :Hygroscopic, -20°C Freezer, Under inert atmosphere
溶解性 :DMF (Slightly, Heated), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
外見 :Solid
酸解離定数(Pka) :6.44±0.50(Predicted)
色 :Off-White to Pale Yellow
安定性: :Hygroscopic
InChIKey :NJDRXTDGYFKORP-LLVKDONJSA-N
SMILES :N1(C2CC2)C2=C(C=CC(C3C=CC4=C(C=3)CN[C@@H]4C)=C2OC(F)F)C(=O)C(C(O)=O)=C1
安全情報
絵表示(GHS): | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
注意喚起語: | Danger | ||||||||||||||||||||||||
危険有害性情報: |
|
||||||||||||||||||||||||
注意書き: |
|
説明
Garenoxacin is a new quinolone antimicrobial agent that exhibits a broad spectrum of activity against both Gram-negative and Gram-positive organisms, including the important community-acquired respiratory pathogens S.pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. In addition, it has potent activity against several resistant strains such as multidrug-resistant S.pneumoniae, methicillin-resistant S.aureus (MRSA), and vancomycin-resistant enterococci (VRE). It was launched in Japan as an oral treatment for respiratory tract and otorhinolaryngological infections. As with other quinolone antibiotics marketed in recent years, the mechanism of action of garenoxacin involves dual inhibition of two essential bacterial enzymes, DNA gyrase and topoisomerase IV. The lack of 6-fluoro substituent does not adversely affect its potency of inhibiting DNA gyrase (Escherichia coli, IC50 0.17 mg/mL) or topoisomerase IV (S. aureus, IC50 2.19 mg/ mL).In human pharmacokinetic studies, oral garenoxacin results in dose-proportionate increases of plasma Cmax and AUC values at doses ranging from 50 to 1,200 mg. Its oral bioavailability is about 95%, and the mean terminal half-life is 15.4 h.
The most common adverse events associated with garenoxacin were rash, dizziness, nausea, headache, and pruritus. Garenoxacin is chemically derived in a sequence of 14 steps, 12 of which entail the construction of a key quinolone intermediate, 7-bromo-1- cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ethyl ester. Subsequently, Suzuki cross-coupling reaction of this intermediate with (R)-[1-methyl-2-(trityl)isoindolin-5-yl]boronic acid, followed by deprotection of the trityl group and ester hydrolysis with hydrochloric acid gives garenoxacin. The chiral isoindoline reagent is obtained from racemic 5-bromo-2-methylisoindoline via coupling with N-CBZ-L-phenylalanine, separation of diastereomers by chromatography, cleavage of the chiral auxiliary, N-tritylation, halogen-metal exchange with butyllithium, and boronation with triisopropyl borate.
関連商品価格
- アニソール
¥1250-260000 - p-アニスアルデヒド
¥1800-163200 - アクリル酸メチル
¥1500-32900